Shire's long-acting Intuniv wins ADHD nod in Europe; Mylan cancels 'stichting' it adopted to fend off Teva;

@FiercePharma: Consumer ranking of fast-food chains' antibiotics in meat calls out FDA, industry for change. FierceAnimalHealth report | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Ireland pharma biz going to the dogs, so to speak. Nextvet picks up biologics plant there. Item | Follow @EricPFierce

@CarlyHFierce: Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Shire ($SHPG) won European approval for its ADHD drug Intuniv to treat children and adolescents with the disorder; the treatment is already cleared by the FDA. Release

> Mylan ($MYL) said it has moved to cancel the Dutch "stichting" vehicle it created earlier this year to fend off a takeover attempt by Teva Pharmaceutical Industries ($TEVA). Report

> Novartis ($NVS) will start manufacturing its blockbuster-to-be heart failure drug Entresto in Singapore. Report

> India's Strides Arcolab bought two CNS-focused divisions from Sun Pharma; the Solus and Solus Care units were inherited in Sun's acquisition of the embattled Ranbaxy Laboratories. Release

Medical Device News

@FierceMedDev: ICYMI: Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI last week: Google hires top government brain scientist to probe mental illness. Story | Follow @StacyALawrence

@EmilyWFierce: Some light reading on Otsuka and Proteus' antipsychotic with a built-in sensor. Wired story | Follow @EmilyWFierce

> The NBA's studying wearable monitors. Will players soon wear them during games? More

> CMS proposal to restrict coverage of artificial limbs facing pushback from amputees. Article

Biotech News

@FierceBiotech: COMMENTARY: Why would Martin Shkreli hike an old drug price by 5000%? Only a 'moron' would ask. More | Follow @FierceBiotech

@JohnCFierce: One win, one loss in Merck's PhIII double header for C diff. Story | Follow @JohnCFierce

@DamianFierce: Filed under Roche Hubris Watch: Reuters article | Follow @DamianFierce

> In Addyi's shadow, Richter walks away from a female libido drug. Report

> Gilead's new pangenotype hep C combo scores stellar results in PhIII. Story

> UniQure beats a path to Phase III after a 'promising' gene therapy trial. Article

Animal Health News

> Science think tank calls for global phaseout of antibiotics in agriculture. More

> Merck pioneers injectable vaccine for common pig disease. Item

> VetStem launches trial of drug-free method for preventing hemorrhage in horses. Story

> Consumer ranking of fast-food chains' antibiotics in meat calls out FDA, industry for change. Article

> ViroVet spins out of Aratana with focus on livestock health. Report

Biotech IT News

> Traders pay SEC $30M to settle newswire hacking case. More

> Google lures NIH mental health chief to life sciences team. News

> Harvard connection helps WuXi NextCODE land Chinese hospital contract. Report

> Microsoft lands cloud genomics infrastructure deal with UC Santa Cruz. Article

> Number of clinical trials to use wearables nears 300. Story

Pharma Marketing News

> More followers and more daily tweeting as Big Pharma's Twitter presence grows. Story

> Sanofi, Pfizer said to be among suitors for Mexico's Rimsa. Item

> Janssen's latest Prezcobix effort taps HIV activists to curate patient-story contest. More

> For sale: Orange paint. It might just become your brand's signature. Editor's Corner

> Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you. Article

And Finally... The Department of Health and Human Services says it will take steps to increase access to treatments for opioid dependence. Report